Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
A five-day inspection was concluded successfully with no critical and no major observations raised
The inspection was concluded with few procedural observations
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
Subscribe To Our Newsletter & Stay Updated
